Search Results 551-560 of 1134 for ✈[광고텔레:SEOGOT] 구글백링크 상단도배 카지노솔루션홍보 에볼루션알광고 구글에볼루션알광고 홀덤솔루션✈

  1. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis - Mayo Clinic

    The primary hypothesis of the study is that treatment with pacritinib results in a greater proportion of patients achieving ≥ 35% reduction in spleen volume ...

  2. Clinical Trials - Study to Distinguish Mood Disorders

    The goal of this proposed study is to examine the genetic signature of the validated proteomic signature (model) based on a panel of serum proteomic markers ...

  3. A Study to Identify and Characterize LAL-D Patients in High-risk Populations - Mayo Clinic

    The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in ...

  4. Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  5. A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 - Mayo Clinic

    About this study. The purpose of this study is to evaluate the effectiveness, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in ...

  6. A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma - Mayo Clinic

    The purpose of this study is to evaluate three different daratumumab dose schedules to treat participants who have Smoldering Multiple Myeloma. Participation ...

  7. A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC - Mayo Clinic

    TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of ...

  8. Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis - Mayo Clinic

    This trial will consist of three arms: Part A, Part B, and Part C. Part A has two groups. The first group will enroll adult subjects with cystic fibrosis (CF) ...

  9. Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Participation eligibility. Participant ...

  10. Evaluation of a Stress Management Tool - Clinical Trials

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...